Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Bødker JS[au]:

Search results

Items: 38

1.

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients.

Laursen MB, Reinholdt L, Schönherz AA, Due H, Jespersen DS, Grubach L, Ettrup MS, Røge R, Falgreen S, Sørensen S, Bødker JS, Schmitz A, Johnsen HE, Bøgsted M, Dybkær K.

Oncotarget. 2019 Jan 22;10(7):717-731. doi: 10.18632/oncotarget.26588. eCollection 2019 Jan 22.

2.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, Johnson D, Bertsch U, Broyl A, van Duin M, Shah R, Johansen P, Nørgaard MA, Samworth RJ, Sonneveld P, Goldschmidt H, Morgan GJ, Orfao A, Munshi N, Johnson HE, El-Galaly T, Dybkær K, Bøgsted M.

Blood Adv. 2018 Sep 25;2(18):2400-2411. doi: 10.1182/bloodadvances.2018018564.

3.

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.

Nørgaard CH, Jakobsen LH, Gentles AJ, Dybkær K, El-Galaly TC, Bødker JS, Schmitz A, Johansen P, Herold T, Spiekermann K, Brown JR, Klitgaard JL, Johnsen HE, Bøgsted M.

PLoS One. 2018 Mar 7;13(3):e0193249. doi: 10.1371/journal.pone.0193249. eCollection 2018.

4.

Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma.

Marcussen M, Sønderkær M, Bødker JS, Andersen M, Nielsen S, Vesteghem C, Christiansen I, Bergmann OJ, Bøgsted M, Dybkær K, Vyberg M, Johnsen HE.

PLoS One. 2018 Jan 16;13(1):e0190709. doi: 10.1371/journal.pone.0190709. eCollection 2018.

5.

A systematic review of molecular responses to cancer therapy in normal human mucosa.

Marcussen M, Skrubbeltrang C, Bødker JS, Christiansen I, Bøgsted M, Dybkær K, Bergmann OJ, Johnsen HE.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Oct;124(4):355-366. doi: 10.1016/j.oooo.2017.08.002. Epub 2017 Aug 15. Review.

PMID:
29042035
6.

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.

Nielsen KR, Rodrigo-Domingo M, Steffensen R, Baech J, Bergkvist KS, Oosterhof L, Schmitz A, Bødker JS, Johansen P, Vogel U, Vangsted A, Dybkær K, Bøgsted M, Johnsen HE.

Leuk Lymphoma. 2017 Nov;58(11):2695-2704. doi: 10.1080/10428194.2017.1306643. Epub 2017 Apr 9.

PMID:
28393658
7.

Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission.

Bødker JS, Severinsen MT, El-Galaly TC, Brøndum RF, Laursen MB, Falgreen S, Nyegaard M, Schmitz A, Jakobsen LH, Schönherz AA, Due H, Reinholdt L, Bøgsted M, Dybkær K, Johnsen HE.

Exp Hematol Oncol. 2017 Jan 11;6:3. doi: 10.1186/s40164-016-0063-0. eCollection 2017.

8.

Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.

Marcussen M, Bødker JS, Christensen HS, Johansen P, Nielsen S, Christiansen I, Bergmann OJ, Bøgsted M, Dybkær K, Vyberg M, Johnsen HE.

PLoS One. 2017 Jan 4;12(1):e0169286. doi: 10.1371/journal.pone.0169286. eCollection 2017.

9.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

10.

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine.

Falgreen S, Ellern Bilgrau A, Brøndum RF, Hjort Jakobsen L, Have J, Lindblad Nielsen K, El-Galaly TC, Bødker JS, Schmitz A, H Young K, Johnsen HE, Dybkær K, Bøgsted M.

PLoS One. 2016 Oct 4;11(10):e0163711. doi: 10.1371/journal.pone.0163711. eCollection 2016.

11.

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.

Reinholdt L, Laursen MB, Schmitz A, Bødker JS, Jakobsen LH, Bøgsted M, Johnsen HE, Dybkær K.

Biomark Res. 2016 Jun 14;4:12. doi: 10.1186/s40364-016-0067-2. eCollection 2016.

12.

Characterization of memory B cells from thymus and its impact for DLBCL classification.

Bergkvist KS, Nørgaard MA, Bøgsted M, Schmitz A, Nyegaard M, Gaihede M, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Urup T, El-Galaly TC, Madsen J, Bødker JS, Dybkær K, Johnsen HE.

Exp Hematol. 2016 Oct;44(10):982-990.e11. doi: 10.1016/j.exphem.2016.06.001. Epub 2016 Jun 11.

PMID:
27297329
13.

miR-155 as a Biomarker in B-Cell Malignancies.

Due H, Svendsen P, Bødker JS, Schmitz A, Bøgsted M, Johnsen HE, El-Galaly TC, Roug AS, Dybkær K.

Biomed Res Int. 2016;2016:9513037. doi: 10.1155/2016/9513037. Epub 2016 May 16. Review.

14.

Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates.

Bilgrau AE, Falgreen S, Petersen A, Kjeldsen MK, Bødker JS, Johnsen HE, Dybkær K, Bøgsted M.

BMC Bioinformatics. 2016 Apr 11;17:159. doi: 10.1186/s12859-016-0997-6.

15.

High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.

Marques SC, Ranjbar B, Laursen MB, Falgreen S, Bilgrau AE, Bødker JS, Jørgensen LK, Primo MN, Schmitz A, Ettrup MS, Johnsen HE, Bøgsted M, Mikkelsen JG, Dybkær K.

Exp Hematol. 2016 Apr;44(4):238-46.e2. doi: 10.1016/j.exphem.2015.12.007. Epub 2016 Feb 17.

PMID:
26854484
16.

Long Noncoding RNA Expression during Human B-Cell Development.

Petri A, Dybkær K, Bøgsted M, Thrue CA, Hagedorn PH, Schmitz A, Bødker JS, Johnsen HE, Kauppinen S.

PLoS One. 2015 Sep 22;10(9):e0138236. doi: 10.1371/journal.pone.0138236. eCollection 2015.

17.

Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma.

Nielsen KR, Steffensen R, Haunstrup TM, Bødker JS, Dybkær K, Baech J, Bøgsted M, Johnsen HE.

Leuk Lymphoma. 2015;56(12):3257-66. doi: 10.3109/10428194.2015.1058936. Epub 2015 Jul 7. Review.

PMID:
26044172
18.

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.

Falgreen S, Dybkær K, Young KH, Xu-Monette ZY, El-Galaly TC, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Bøgsted M.

BMC Cancer. 2015 Apr 8;15:235. doi: 10.1186/s12885-015-1237-6.

19.

Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.

Dybkær K, Bøgsted M, Falgreen S, Bødker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, Møller MB, Samworth RJ, Shah RD, Johansen P, El-Galaly TC, Young KH, Johnsen HE.

J Clin Oncol. 2015 Apr 20;33(12):1379-88. doi: 10.1200/JCO.2014.57.7080. Epub 2015 Mar 23.

20.

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies.

Marques SC, Laursen MB, Bødker JS, Kjeldsen MK, Falgreen S, Schmitz A, Bøgsted M, Johnsen HE, Dybkaer K.

Oncotarget. 2015 Jan 1;6(1):7-25. Review.

21.

Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank.

Rasmussen SM, Bilgrau AE, Schmitz A, Falgreen S, Bergkvist KS, Tramm AM, Baech J, Jacobsen CL, Gaihede M, Kjeldsen MK, Bødker JS, Dybkaer K, Bøgsted M, Johnsen HE.

Cytometry B Clin Cytom. 2015 Jan;88(1):40-9. doi: 10.1002/cyto.b.21192. Epub 2014 Oct 20.

22.

Stable Phenotype Of B-Cell Subsets Following Cryopreservation and Thawing of Normal Human Lymphocytes Stored in a Tissue Biobank.

Rasmussen SM, Bilgrau AE, Schmitz A, Falgreen S, Bergkvist KS, Tramm AM, Baech J, Jacobsen CL, Gaihede M, Kjeldsen MK, Bødker JS, Dybkaer K, Bøgsted M, Johnsen HE.

Cytometry B Clin Cytom. 2014 Sep 20. doi: 10.1002/cytob.21192. [Epub ahead of print]

23.

Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.

Laursen MB, Falgreen S, Bødker JS, Schmitz A, Kjeldsen MK, Sørensen S, Madsen J, El-Galaly TC, Bøgsted M, Dybkær K, Johnsen HE; Myeloma Stem Cell Network.

Exp Hematol. 2014 Nov;42(11):927-38. doi: 10.1016/j.exphem.2014.07.263. Epub 2014 Jul 27. Review.

PMID:
25072621
24.

Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition.

Falgreen S, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Dybkær K, Bøgsted M.

BMC Bioinformatics. 2014 Jun 5;15:168. doi: 10.1186/1471-2105-15-168.

25.

SOX11 as a minimal residual disease marker for Mantle cell lymphoma.

Simonsen AT, Sørensen CD, Ebbesen LH, Bødker JS, Bentzen HH, Nyvold CG.

Leuk Res. 2014 Aug;38(8):918-24. doi: 10.1016/j.leukres.2014.04.007. Epub 2014 Apr 28.

PMID:
24878000
26.

Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man.

Bergkvist KS, Nyegaard M, Bøgsted M, Schmitz A, Bødker JS, Rasmussen SM, Perez-Andres M, Falgreen S, Bilgrau AE, Kjeldsen MK, Gaihede M, Nørgaard MA, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Dybkær K, Johnsen HE.

BMC Immunol. 2014 Jan 31;15:3. doi: 10.1186/1471-2172-15-3.

27.

Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.

Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE.

PLoS One. 2013 Dec 20;8(12):e83252. doi: 10.1371/journal.pone.0083252. eCollection 2013.

28.

Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy.

Johnsen HE, Bergkvist KS, Schmitz A, Kjeldsen MK, Hansen SM, Gaihede M, Nørgaard MA, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Bødker JS, Bøgsted M, Dybkær K; Myeloma Stem Cell Network (MSCNET).

Leuk Lymphoma. 2014 Jun;55(6):1251-60. doi: 10.3109/10428194.2013.839785. Epub 2013 Nov 1. Review.

PMID:
23998255
29.

Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor.

Rodrigo-Domingo M, Waagepetersen R, Bødker JS, Falgreen S, Kjeldsen MK, Johnsen HE, Dybkær K, Bøgsted M.

Brief Bioinform. 2014 Jul;15(4):519-33.

30.

Performance comparison of Affymetrix SNP6.0 and cytogenetic 2.7M whole-genome microarrays in complex cancer samples.

Bødker JS, Gyrup C, Johansen P, Schmitz A, Madsen J, Johnsen HE, Bøgsted M, Dybkær K, Nyegaard M.

Cytogenet Genome Res. 2013;139(2):80-7. doi: 10.1159/000345125. Epub 2012 Nov 20.

PMID:
23182917
31.

A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells.

Kloster MB, Bilgrau AE, Rodrigo-Domingo M, Bergkvist KS, Schmitz A, Sønderkær M, Bødker JS, Falgreen S, Nyegaard M, Johnsen HE, Nielsen KL, Dybkaer K, Bøgsted M.

BMC Genomics. 2012 Nov 5;13:596. doi: 10.1186/1471-2164-13-596.

32.

Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.

Nordentoft I, Dyrskjøt L, Bødker JS, Wild PJ, Hartmann A, Bertz S, Lehmann J, Orntoft TF, Birkenkamp-Demtroder K.

BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.

33.

Biochemical properties of plasminogen activator inhibitor-1.

Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, Andreasen PA.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1337-61. Review.

PMID:
19273134
34.

Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.

Komissarov AA, Andreasen PA, Bødker JS, Declerck PJ, Anagli JY, Shore JD.

J Biol Chem. 2005 Jan 14;280(2):1482-9. Epub 2004 Oct 29.

35.

Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.

Durand MK, Bødker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, Wind T, Andreasen PA.

Thromb Haemost. 2004 Mar;91(3):438-49. Review.

PMID:
14983218
36.

Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.

Jensen JK, Durand MK, Skeldal S, Dupont DM, Bødker JS, Wind T, Andreasen PA.

FEBS Lett. 2004 Jan 2;556(1-3):175-9.

37.

Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.

Einholm AP, Pedersen KE, Wind T, Kulig P, Overgaard MT, Jensen JK, Bødker JS, Christensen A, Charlton P, Andreasen PA.

Biochem J. 2003 Aug 1;373(Pt 3):723-32.

38.

Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents.

Bødker JS, Wind T, Jensen JK, Hansen M, Pedersen KE, Andreasen PA.

Eur J Biochem. 2003 Apr;270(8):1672-9.

Supplemental Content

Loading ...
Support Center